These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25447131)

  • 1. Transplantation: induction of chimerism and immune tolerance using belatacept.
    Carney EF
    Nat Rev Nephrol; 2015 Feb; 11(2):66. PubMed ID: 25447131
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates.
    Yamada Y; Ochiai T; Boskovic S; Nadazdin O; Oura T; Schoenfeld D; Cappetta K; Smith RN; Colvin RB; Madsen JC; Sachs DH; Benichou G; Cosimi AB; Kawai T
    Am J Transplant; 2014 Dec; 14(12):2704-12. PubMed ID: 25394378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerance induction: hematopoietic chimerism.
    Kawai T; Sachs DH
    Curr Opin Organ Transplant; 2013 Aug; 18(4):402-7. PubMed ID: 23838644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat.
    Zhu ZX; Fan LY; Wang Q
    Eur Surg Res; 2011; 46(3):109-17. PubMed ID: 21242693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade.
    Chavez H; Beaudreuil S; Abbed K; Taoufic Y; Kriaa F; Charpentier B; Durrbach A
    Transpl Immunol; 2007 Jun; 17(4):243-8. PubMed ID: 17493526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-derived bone marrow transfusion produces mixed chimerism and promotes a Th2 shift in Th1/Th2 balance in rat heterotopic small bowel transplantation.
    Hu A; Li Q; Shi H; Tai Q; Wu L; Xiong J; Fu B; He X
    Dig Liver Dis; 2012 Dec; 44(12):988-94. PubMed ID: 22954489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.
    Grimbert P; Audard V; Diet C; Matignon M; Plonquet A; Mansour H; Desvaux D; Durrbach A; Cohen JL; Lang P
    Nephrol Dial Transplant; 2011 Mar; 26(3):1087-93. PubMed ID: 20667993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimerism studies as an approach for the induction of tolerance to extremity allografts.
    Muramatsu K; Kuriyama R; You-Xin S; Hashimoto T; Matsunaga T; Taguchi T
    J Plast Reconstr Aesthet Surg; 2008 Sep; 61(9):1009-15. PubMed ID: 18573704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reflections on the unique tolerogenicity of bone marrow, the enigma of chimerism and clinical tolerance.
    Monaco AP
    Clin Transpl; 2013; ():157-66. PubMed ID: 25095504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inducing mixed chimerism and transplantation tolerance through allogeneic bone marrow transplantation with costimulation blockade.
    Pree I; Wekerle T
    Methods Mol Biol; 2007; 380():391-403. PubMed ID: 17876108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed chimerism through donor bone marrow transplantation: a tolerogenic cell therapy for application in organ transplantation.
    Pilat N; Hock K; Wekerle T
    Curr Opin Organ Transplant; 2012 Feb; 17(1):63-70. PubMed ID: 22186093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translating transplantation tolerance in the clinic: where are we, where do we go?
    Goldman M; Wood K
    Clin Exp Immunol; 2009 May; 156(2):185-8. PubMed ID: 19250278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinically feasible approach to induce delayed tolerance in recipients of prior kidney or vascularized composite allotransplants.
    Chen B; Xu H; Corbin DR; Ildstad ST
    Transplantation; 2012 Oct; 94(7):671-8. PubMed ID: 22948444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow chimerism and tolerance induced by single-dose cyclophosphamide.
    Okayama J; Ko S; Kanehiro H; Kanokogi H; Hisanaga M; Ohashi K; Sho M; Nagao M; Ikeda N; Kanamura T; Akashi S; Nakajima Y
    J Surg Res; 2004 Jul; 120(1):102-10. PubMed ID: 15172196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic chimerism induces renal and skin allograft tolerance in DLA-identical dogs.
    Tillson M; Niemeyer GP; Welch JA; Brawner W; Swaim SF; Rynders P; Lenz SD; Dean B; Lothrop CD
    Exp Hematol; 2006 Dec; 34(12):1759-70. PubMed ID: 17157174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept.
    Wojciechowski D; Vincenti F
    Curr Opin Organ Transplant; 2010 Dec; 15(6):697-702. PubMed ID: 20930638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic and therapeutic role of regulatory T cells in tolerance through mixed chimerism.
    Pilat N; Wekerle T
    Curr Opin Organ Transplant; 2010 Dec; 15(6):725-30. PubMed ID: 20881493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow chimerism as a strategy to produce tolerance in solid organ allotransplantation.
    Hu M; Alexander SI; Yi S
    Curr Opin Organ Transplant; 2016 Dec; 21(6):595-602. PubMed ID: 27805947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell therapy approaches aiming at minimization of immunosuppression in solid organ transplantation.
    Fändrich F
    Curr Opin Organ Transplant; 2010 Dec; 15(6):703-8. PubMed ID: 20930635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed chimerism.
    Sykes M; Sachs DH
    Philos Trans R Soc Lond B Biol Sci; 2001 May; 356(1409):707-26. PubMed ID: 11375074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.